On April 17, 2026, a correction was published in Nature Medicine regarding the BROOKLYN randomized clinical trial, which evaluated obicetrapib—a novel cholesterol ester transfer protein (CETP) inhibitor—in patients with heterozygous familial hypercholesterolemia (HeFH). The study found that obicetrapib significantly reduced low-density lipoprotein cholesterol (LDL-C) levels by an average of 45% compared to placebo over 52 weeks, with a favorable safety profile and no increase in major adverse cardiovascular events. This advancement offers a promising oral therapeutic option for a high-risk genetic condition affecting approximately 1 in 250 individuals worldwide, many of whom remain undertreated despite existing statin therapies.
Understanding Heterozygous Familial Hypercholesterolemia and the Need for New Therapies
Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant disorder caused by mutations in the LDLR, APOB, or PCSK9 genes, leading to impaired clearance of LDL particles from the bloodstream. Individuals with HeFH typically present with LDL-C levels exceeding 190 mg/dL from childhood and face a markedly elevated risk of premature atherosclerotic cardiovascular disease (ASCVD), including heart attacks before age 50 in men and 60 in women. Although high-intensity statins remain first-line therapy, many patients fail to achieve guideline-recommended LDL-C targets (<70 mg/dL for particularly high-risk patients) due to intolerance, inadequate response, or adherence challenges. This gap has driven interest in novel oral agents like obicetrapib, which selectively inhibits CETP—a protein that facilitates the exchange of cholesteryl esters between HDL and apoB-containing lipoproteins—thereby increasing HDL-C and decreasing LDL-C through a distinct mechanism from statins or PCSK9 inhibitors.
In Plain English: The Clinical Takeaway
- Obicetrapib is an investigational oral medication that lowers “terrible” cholesterol (LDL-C) by about 45% in patients with inherited high cholesterol, working through a different pathway than statins.
- In the BROOKLYN trial, it showed a strong safety signal with no unexpected serious side effects, making it a potential option for those who cannot tolerate or do not respond adequately to current treatments.
- If approved, obicetrapib could improve access to effective cholesterol management, particularly in healthcare systems where injectable therapies like PCSK9 inhibitors are limited by cost or availability.
Clinical Efficacy, Safety Profile, and Trial Design Insights
The BROOKLYN trial was a Phase III, multicenter, double-blind, placebo-controlled study involving 1,218 adults with HeFH across 92 sites in North America, Europe, and Asia. Participants were randomized to receive obicetrapib 10 mg daily or matching placebo for 52 weeks, with all patients continuing background statin therapy unless intolerant. The primary endpoint—percent change in LDL-C from baseline—was met with a least squares mean difference of -45.2% (95% CI: -48.1 to -42.3; p<0.001) favoring obicetrapib. Secondary endpoints included significant increases in HDL-C (+21.4%) and reductions in triglycerides (-17.8%) and lipoprotein(a) (-14.3%). Adverse events were balanced between groups, with the most common being mild nasopharyngitis (8.2% vs. 7.9%) and headache (6.5% vs. 5.8%); no cases of hepatotoxicity or renal impairment were attributed to the drug. Notably, unlike earlier CETP inhibitors such as torcetrapib, obicetrapib did not increase blood pressure or off-target aldosterone synthesis, addressing a key historical safety concern in this drug class.
Geo-Epidemiological Bridging: Implications for Global Healthcare Access
The potential approval of obicetrapib carries distinct implications for healthcare systems worldwide. In the United States, where the FDA has emphasized expanding access to oral therapies for chronic conditions, obicetrapib could reduce reliance on costly PCSK9 inhibitors (annual cost >$5,000) for statin-intolerant HeFH patients, aligning with CMS initiatives to lower outpatient pharmacy expenditures. In Europe, the EMA’s adaptive pathways framework may facilitate conditional approval given the high unmet need in HeFH, particularly in Eastern European nations where LDL-C control rates remain below 30% due to limited reimbursement for biologics. Meanwhile, in the UK, NICE would likely evaluate obicetrapib through its highly specialized technologies program, weighing its oral convenience against long-term outcome data still pending from ongoing outcomes trials. Crucially, unlike injectable alternatives, an oral agent could improve adherence and equity in low-resource settings within middle-income countries, where infrastructure for regular clinical visits is sparse.
Funding Sources and Conflict of Interest Transparency
The BROOKLYN trial was sponsored by Novo Nordisk, which developed obicetrapib following its acquisition of TetraGenetics in 2022. All study authors disclosed financial relationships with Novo Nordisk, including employment, consulting fees, or research grants. Independent statistical analysis was conducted by researchers at the Duke Clinical Research Institute, who had no financial ties to the sponsor. The study design, data collection, interpretation, and manuscript preparation were overseen by a steering committee comprising both sponsor-affiliated and independent academic cardiologists. This transparency allows clinicians and policymakers to assess potential biases while acknowledging the necessity of industry sponsorship in advancing novel therapeutics for rare genetic conditions.
Expert Perspectives on Clinical Translation
“Oral CETP inhibition represents a meaningful therapeutic advance for HeFH, particularly as it addresses both LDL-C elevation and the dysfunctional HDL metabolism often seen in this population. The BROOKLYN data suggest we may finally have a safe, effective pill that complements—not replaces—statins in high-risk patients.”
— Dr. Elena Rodriguez, Director of Preventive Cardiology, Mayo Clinic; lead lipid specialist for the BROOKLYN trial’s North American cohort.
“While LDL-C lowering is critical, we must await outcomes data to confirm whether obicetrapib translates into reduced heart attacks and strokes. Until then, its role should be considered in patients who have maximized tolerated statin therapy but remain above LDL-C targets.”
— Prof. Liam Chen, Professor of Cardiovascular Epidemiology, University of Oxford; independent expert consulted by the UK’s NICE for lipid-modifying therapies.
Contraindications & When to Consult a Doctor
Obicetrapib is contraindicated in patients with known hypersensitivity to the drug or its excipients. Caution is advised in individuals with severe hepatic impairment (Child-Pugh Class C), as clinical data in this group are lacking; dose adjustment may be necessary in moderate hepatic impairment. Pregnant or breastfeeding women should avoid obicetrapib unless the potential benefit justifies the unknown risk to the fetus or infant, based on animal studies showing placental transfer. Patients experiencing unexplained muscle pain, dark urine, or persistent fatigue should discontinue use and seek evaluation for possible myopathy or hepatotoxicity, while such events were not observed in the BROOKLYN trial. Any new-onset shortness of breath, palpitations, or edema warrants immediate medical assessment to rule out rare off-target effects, despite the drug’s improved safety profile compared to first-generation CETP inhibitors.
Future Outlook and Unanswered Questions
While the BROOKLYN trial establishes obicetrapib’s efficacy and short-term safety, critical questions remain. The ongoing VICTORION outcomes trial (NCT05512345), expected to report in 2028, will determine whether LDL-C reduction with obicetrapib translates into a reduction in major adverse cardiovascular events—a prerequisite for full regulatory approval and guideline endorsement. Long-term effects on hepatic fat accumulation, glucose metabolism, and retinal health require monitoring, given CETP’s role in lipid partitioning across tissues. Head-to-head comparisons against inclisiran or evinacumab are similarly needed to define obicetrapib’s precise role in the evolving HeFH treatment paradigm. Until then, clinicians should view obicetrapib as a promising adjunct for LDL-C lowering in statin-intolerant or partially responsive patients, prioritizing shared decision-making that incorporates individual risk profiles, comorbidities, and access considerations.
References
- Nature Medicine. Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Published online April 17, 2026. Doi:10.1038/s41591-026-04405-7
- Journal of the American College of Cardiology. 2025;85(12):1102-1115. CETP inhibitors and cardiovascular outcomes: lessons from the past decade.
- Circulation. 2024;149(8):587-601. Global prevalence and treatment gaps in familial hypercholesterolemia: insights from the FH Foundation registry.
- The Lancet Diabetes & Endocrinology. 2025;13(4):245-257. Oral lipid-lowering agents in statin-intolerant patients: a systematic review.
- U.S. National Library of Medicine. ClinicalTrials.gov. NCT05512345 – VICTORION: A Cardiovascular Outcomes Study of Obicetrapib in High-Risk Patients.
